Literature DB >> 10172695

The cost of Alzheimer's disease. Will drug treatment ease the burden?

W Max1.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 10172695     DOI： 10.2165/00019053-199609010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  30 in total

1.  Tacrine for treating Alzheimer's disease.

Authors:  G W Small
Journal:  JAMA       Date:  1992-11-11       Impact factor: 56.272

2.  Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.

Authors:  G Chatellier; L Lacomblez
Journal:  BMJ       Date:  1990-02-24

Review 3.  Management of patients with Alzheimer's disease.

Authors:  G L Odenheimer
Journal:  Pharmacotherapy       Date:  1991       Impact factor: 4.705

4.  Tacrine in Alzheimer's disease.

Authors:  B Davies; D Andrewes; R Stargatt; D Ames; V Tuckwell; S Davis
Journal:  Lancet       Date:  1989-07-15       Impact factor: 79.321

5.  Evaluation of the costs of caring for the senile demented elderly: a pilot study.

Authors:  T W Hu; L F Huang; W S Cartwright
Journal:  Gerontologist       Date:  1986-04

6.  Tacrine in Alzheimer's disease.

Authors:  S A Eagger; R Levy; B J Sahakian
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

7.  Constellation of risks and processes seen in search for Alzheimer's clues.

Authors:  P Cotton
Journal:  JAMA       Date:  1994-01-12       Impact factor: 56.272

8.  Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

Authors:  K L Davis; R C Mohs
Journal:  Am J Psychiatry       Date:  1982-11       Impact factor: 18.112

9.  The economic cost of senile dementia in the United States, 1985.

Authors:  L F Huang; W S Cartwright; T W Hu
Journal:  Public Health Rep       Date:  1988 Jan-Feb       Impact factor: 2.792

10.  The costs of family contributions to the care of persons with dementia.

Authors:  M Stommel; C E Collins; B A Given
Journal:  Gerontologist       Date:  1994-04
View more
  11 in total

Review 1.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Cost-of-illness studies. Useful for health policy?

Authors:  M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

Review 3.  Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  H M Lamb; K L Goa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  The pharmacoeconomics of dementia therapies. Bringing the clinical, research and economic perspectives together.

Authors:  F J Molnar; W B Dalziel
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

5.  Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.

Authors:  Anders Wimo; Bengt Winblad; Albrecht Stöffler; Yvonne Wirth; Hans-Jörg Möbius
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Donepezil. Pharmacoeconomic implications of therapy.

Authors:  R H Foster; G L Plosker
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 7.  Galantamine: a review of its use in Alzheimer's disease.

Authors:  L J Scott; K L Goa
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

8.  Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study.

Authors:  G Nappi; G Bono; P Merlo; A Borromei; C Caltagirone; C Lomeo; N Martucci; G Fabbrini; K Annoni; A Battaglia
Journal:  Clin Drug Investig       Date:  1997-06       Impact factor: 2.859

Review 9.  Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.

Authors:  Anders Wimo
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.